| The COSMYC Trial (COmbined Suppression of MYC) NCT06922318 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | Phase 2 | August 19, 2025 |
| Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II) NCT07142967 NYU Langone Health | Recruiting | N/A | August 15, 2025 |
| Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer NCT05873192 M.D. Anderson Cancer Center | Recruiting | Phase 2 | June 3, 2025 |
| Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer NCT06734130 H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting | Phase 2 | January 10, 2025 |
| A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study NCT06531499 Novartis Pharmaceuticals | Active, not recruiting | Phase 1 | November 11, 2024 |
| NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. NCT06379217 Novartis Pharmaceuticals | Active, not recruiting | Phase 1 | July 29, 2024 |
| Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer NCT04176081 University Health Network, Toronto | Not yet recruiting | Phase 2 | July 2, 2024 |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial NCT06378866 Mayo Clinic | Recruiting | Phase 2 | June 3, 2024 |
| Cardiometabolic Consequences of the Loss of Ovarian Function NCT06264882 University of Colorado, Denver | Recruiting | Phase 4 | June 1, 2024 |
| ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer NCT06397703 NYU Langone Health | Recruiting | Phase 2 | April 16, 2024 |
| NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial NCT06066437 M.D. Anderson Cancer Center | Recruiting | Phase 1, Phase 2 | March 29, 2024 |
| Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers NCT06282588 Cancer Research Antwerp | Recruiting | Phase 2, Phase 3 | December 13, 2023 |
| ETHAN - ET for Male BC NCT05501704 Jose Pablo Leone | Recruiting | Phase 2 | October 11, 2023 |
| Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer NCT06059118 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | Phase 2 | October 4, 2023 |
| Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer NCT05917860 Turku University Hospital | Active, not recruiting | Phase 1 | July 18, 2023 |
| Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer NCT05628363 Washington University School of Medicine Results posted | Active, not recruiting | N/A | January 18, 2023 |
| Prostate Medication, Metabolism and Gut Microbiota NCT06001619 Turku University Hospital | Recruiting | Phase 4 | December 1, 2022 |
| Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) NCT05241860 Alliance for Clinical Trials in Oncology Results posted | Active, not recruiting | Phase 2 | November 21, 2022 |
| First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer NCT05189457 H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting | Phase 2 | January 25, 2022 |
| Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer NCT04989946 University of Wisconsin, Madison | Active, not recruiting | Phase 1, Phase 2 | December 16, 2021 |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial NCT05050084 NRG Oncology | Active, not recruiting | Phase 3 | December 6, 2021 |
| Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study) NCT05057546 University of Colorado, Denver | Active, not recruiting | Phase 4 | November 22, 2021 |
| A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy NCT04455750 Alliance for Clinical Trials in Oncology | Active, not recruiting | Phase 3 | October 14, 2021 |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer NCT04787744 VA Office of Research and Development | Active, not recruiting | Phase 2, Phase 3 | July 1, 2021 |
| Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer NCT04734730 City of Hope Medical Center | Recruiting | Phase 2 | May 4, 2021 |
| A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer NCT04633252 National Cancer Institute (NCI) | Recruiting | Phase 1, Phase 2 | February 23, 2021 |
| Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial NCT04513717 NRG Oncology | Active, not recruiting | Phase 3 | January 21, 2021 |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging NCT04423211 ECOG-ACRIN Cancer Research Group | Recruiting | Phase 3 | October 8, 2020 |
| Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors NCT04126070 Xiao X. Wei, MD Results posted | Active, not recruiting | Phase 2 | May 11, 2020 |
| Bioenergetic Effects of Aging and Menopause (BEAM) NCT04043520 University of Colorado, Denver | Recruiting | Phase 4 | September 24, 2019 |
| REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer NCT03951831 Mark Stein | Active, not recruiting | Phase 2 | May 16, 2019 |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer NCT03678025 SWOG Cancer Research Network | Recruiting | Phase 3 | September 24, 2018 |
| Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer NCT03361735 City of Hope Medical Center Results posted | Active, not recruiting | Phase 2 | August 29, 2018 |
| ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer NCT02972060 European Organisation for Research and Treatment of Cancer - EORTC | Active, not recruiting | Phase 2 | December 1, 2017 |
| Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer NCT02799706 European Organisation for Research and Treatment of Cancer - EORTC | Active, not recruiting | Phase 3 | September 25, 2017 |
| Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery NCT03070886 NRG Oncology | Active, not recruiting | Phase 2, Phase 3 | April 5, 2017 |
| Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study) NCT03703778 Chinese University of Hong Kong | Active, not recruiting | — | May 22, 2016 |
| Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer NCT01990196 Jonsson Comprehensive Cancer Center | Active, not recruiting | Phase 2 | September 23, 2014 |
| Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer NCT01786265 M.D. Anderson Cancer Center | Active, not recruiting | Phase 2 | February 5, 2013 |
| Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation NCT01746849 Memorial Sloan Kettering Cancer Center | Active, not recruiting | Phase 2 | Dec 2012 |